- **Revenue Supercharge**: 20% YoY growth to $851M, driven by Cologuard's 22% surge and 0.25M+ new screenings. 
- **Cologuard Plus Dominance**: 95% sensitivity, 4 top payers contracted, targeting 30%+ volume. 
- **Cancerguard Launch**: Direct-to-consumer ads, 200k+ provider network engagement. 
- **Cash Flow Powerhouse**: $236M free cash flow YTD (+270%), 16% EBITDA margins. 
- **Freenome Milestone**: V2 data Q4, V1 FDA review for CRC blood test. 
- **2026 Vision**: 15%+ CAGR, 20%+ screening growth pace, 70%+ rescreen penetration.

**【CEO Summary Section】**
- **Record Q3 Results**: Total revenue of $851 million, up 20% YoY, driven by Cologuard's 22% growth and 0.25 million additional screenings. 
- **Cologuard Plus Momentum**: 95% sensitivity and 94% specificity, with 4 of top 10 payers now contracted. 
- **New Product Launches**: Cancerguard (multi-cancer test) and Freenome's V2 CRC blood test in development. 
- **Commercial Expansion**: 12,000+ new providers ordered Cologuard Q3, active ordering providers reach 200,000. 
- **Rescreen Penetration**: Mid-50s% of eligible patients, targeting 70%+ with automation. 

**【CFO Financial Commentary】**
- **Revenue Growth**: Screening ($666M, +22%), Precision Oncology ($183M, +12%). 
- **Profitability**: Adjusted EBITDA $135M (+37%), margins 16% (vs 14% prior). 
- **Cash Flow**: Free cash flow $190M Q3, $236M YTD (+270%). 
- **Guidance Update**: Full year revenue $3.22-3.235B, EBITDA $470-480M. 
- **Gross Margin**: 71% (-100bps due to care gap shipments). 

**【Q&A Highlights】**
- **Care Gap Impact**: 300-400bps price impact on 2026 growth, 30% of volume contracted. 
- **Cancerguard Strategy**: Direct-to-consumer marketing, leveraging 200k+ provider network. 
- **Freenome Update**: V2 data expected Q4, V1 FDA review ongoing. 
- **2026 Outlook**: 15%+ CAGR vs long-term target, 20%+ screening growth pace. 
- **MRD Progress**: Breast cancer evidence generation, MAESTRO tech launch 2026.

Exact Sciences Corporation (EXAS) Q3 2025 Earnings Call Transcript

- **Record Q2 Growth**: 16% core revenue growth ($807M), $138M EBITDA (+26%), and 1.3M test results.
- **Guidance Uptick**: +$55M revenue midpoint, +$25M EBITDA, driven by Cologuard Plus and productivity plan.
- **Strategic Acquisitions**: Exclusive Freenome blood test rights, Medicare Oncodetect coverage, and Cancerguard launch.
- **Cost Optimization**: $150M+ annual savings by 2026, $50M+ in 2025 guidance.
- **Market Leadership**: Cologuard brand awareness > colonoscopy, 200K+ providers ordering, 120K+ cancer diagnoses since launch.

**【CEO Summary Section】**
- Delivered record 1.3 million test results, 16% year-over-year core revenue growth, and $138 million adjusted EBITDA.
- Raised 2025 revenue guidance by $55 million midpoint to $3.13-$3.17 billion and EBITDA by $25 million to $455-$475 million.
- Expanded Cologuard Plus in-network with 2 top payers (Humana, Centene), securing Medicare coverage for Oncodetect, and announcing a $150 million annual productivity plan by 2026.
- Launched Cancerguard multi-cancer early detection test, leveraging 1,000+ reps and ExactNexus platform to target $25 billion addressable market.

**【CFO Financial Commentary】**
- Q2 revenue: $807 million (16% YoY growth), screening revenue $628 million (+18%), precision oncology $179 million (+9%).
- Adjusted EBITDA: $138 million (+26%), margin +130bps driven by Cologuard Plus pricing and productivity gains.
- Free cash flow: $47 million (vs. -$48 million YoY), with $858 million cash on hand.
- 2025 productivity plan: $150M annual savings by 2026, $50M+ included in 2025 guidance, $90-95M restructuring costs in 2025.

**【Q&A Key Highlights】**
- **Freenome Deal Strategy**: Acquired exclusive rights to blood-based CRC test with optionality for next-gen version. Test submitted to FDA, expected 12-18 month timeline. Viewed as complementary to Cologuard for 45M+ screening-resistant patients.
- **Blood Test Performance**: Freenome's B1 test achieved 81% cancer sensitivity, 14% APL at 90% specificity. Internal program continues with exit clause if APL <19%.
- **Market Dynamics**: Blood-based CRC <5% of market; Cologuard brand awareness exceeds colonoscopy. Competitors' activity driving Cologuard utilization growth.
- **Multi-Cancer Test**: Cancerguard launch supported by 1,000+ reps and ExactNexus platform. Targets 70% of cancers without screening solutions.
- **Productivity Plan**: Focus on G&A efficiencies (external spend reduction, AI/automation), with $150M+ annual savings by 2026.


Exact Sciences Corporation (EXAS) Q2 2025 Earnings Call Transcript

- **Revenue Growth**: Q1 core revenue up 11%, with screening revenue +14% driven by rescreens and new providers.
- **Profitability**: Adjusted EBITDA +61% to $63M, margin up 280bps; free cash flow breakeven vs -$120M YoY.
- **Cologuard Plus**: 30,000+ tests in first month, Medicare coverage, 40% reduction in false positives.
- **Pipeline Momentum**: Blood test mid-summer data, Cancerguard H2 launch, Oncodetect Medicare filing.
- **Guidance Update**: 2025 revenue raised to $3.07-3.12B (+$40M), EBITDA to $425-455M (+$50M).

**【CEO Opening Remarks】**
- Delivered 1.2 million patient results in Q1, with core revenue up 11% YoY.
- Adjusted EBITDA increased 61% to $63 million, driven by volume leverage and cost-cutting initiatives.
- Launched Cologuard Plus with Medicare coverage, achieving 30,000+ tests in first month.
- Customer satisfaction at all-time high, with 190,000+ providers ordering in Q1.
- Rescreen program now accounts for >25% of revenue, with adherence improving 2-3% annually.

**【CFO Financial Highlights】**
- Q1 revenue: $707 million (11% YoY growth), beating midpoint of guidance by $19 million.
- Screening revenue: $540 million (+14%), driven by rescreens, care gap programs, and new providers.
- Precision Oncology: $167 million (+4%), led by international Oncotype DX adoption.
- Adjusted EBITDA margin expanded 280bps to 18.8%, G&A expenses down 7% YoY.
- Free cash flow breakeven in Q1, up $120 million YoY; full-year guidance for record cash flow.
- Raised 2025 revenue guidance to $3.07-3.12 billion (+$40M midpoint), EBITDA to $425-455 million.

**【Q&A Key Takeaways】**
1. **Commercial Execution**: 
   - Field team engagement up 30% YoY, with 10% YoY increase in new provider orders.
   - Cologuard Plus pricing benefit to drive 15%+ screening growth in H2.
   - Customer-initiated ordering (DTC) up triple digits YoY.

2. **Pipeline Progress**: 
   - Blood-based colon cancer test on track for mid-summer top-line data.
   - Cancerguard multi-cancer screening launch planned for H2 2025.
   - Oncodetect (molecular residual disease test) seeking Medicare reimbursement.

3. **Margins & Cash Flow**: 
   - Gross margin improvement from Cologuard Plus (40% lower false positives, 5-6% lower cost).
   - Sales & marketing investments focused on new product launches (Oncodetect, Cancerguard).
   - 2025 guidance implies 35% EBITDA growth and 250bps margin expansion.


Exact Sciences (EXAS)-1 May 25-2025 Q1 Earnings call transcript

- **2024 Growth Milestones**: 11% core revenue, 48% EBITDA expansion, $1.04B free cash flow. FDA approves Cologuard Plus, Oncodetect, and Cancerguard.
- **2025 Outlook**: 13% Screening growth (2 pts from Cologuard Plus), 5% Precision Oncology growth. 220bps EBITDA margin expansion via volume leverage and cost control.
- **Product Differentiation**: Cologuard Plus (95% sensitivity), Oncodetect (50x recurrence risk), and Cancerguard (98.5% specificity). Blood-based CRC test on track for mid-2025 results.
- **Financial Strength**: Free cash flow >$1B, debt-free balance sheet, reinvesting savings into growth initiatives.


**【CEO Opening Remarks】**
- **2024 Key Achievements**: Delivered 4.6M+ cancer test results, 11% core revenue growth, 48% EBITDA expansion, and FDA approval for Cologuard Plus. Launched Oncodetect and Cancerguard, with >230K patients served in Precision Oncology.
- **2025 Growth Drivers**: Cologuard Plus adoption (15% of volumes), rescreening rates (2M eligible in 2025), and launches of Oncodetect (Q2) and Cancerguard (H2). Free cash flow doubled to $1.04B, enabling debt repayment.

**【CFO Financial Review】**
- **Q4 2024 Results**: Total revenue $718M (+10%), Screening $553M (+14%), Precision Oncology $161M. Adjusted EBITDA $75M (+52%), free cash flow $162M. Medicare pricing for Cologuard Plus at $592, 15% of volumes.
- **2025 Guidance**: Revenue $3.025B-$3.085B (11% growth), EBITDA $410M-$440M. Screening growth 13% (2 pts from Cologuard Plus), Oncotype DX international double-digit growth. 220bps EBITDA margin expansion via volume leverage and G&A efficiency.

**【Q&A Highlights】**
- **Cologuard Plus Pricing**: 16% price increase for Medicare, 2 pts of 2025 Screening growth. Commercial payer contracts expected to expand over 18-24 months. Rescreen adherence rate at all-time high.
- **Oncodetect Launch**: Q2 2025, 50x recurrence risk sensitivity vs. negative, 10-month lead vs. imaging. ASCO data submission for Medicare reimbursement.
- **Competitive Landscape**: Blood-based CRC test BLUE-C study results mid-2025. Cologuard Plus differentiation via 95% sensitivity vs. colonoscopy.
- **Financial Leverage**: G&A expenses down 400bps, reinvesting savings into growth (e.g., Cologuard Plus education, Oncodetect salesforce). Free cash flow >$1B enables disciplined capital allocation.


Exact Sciences Corporation (EXAS) Q4 2024 Earnings Call Transcript

Exact Sciences (EXAS)-5 Nov 24-2024 Q3 Earnings call transcript

Exact Sciences (EXAS)-31 Jul 24-2024 Q2 Earnings call transcript

Exact Sciences (EXAS)-8 May 24-2024 Q1 Earnings call transcript

Exact Sciences (EXAS)-21 Feb 24-2023 Q4 Earnings call transcript

Exact Sciences (EXAS)-1 Nov 23-2023 Q3 Earnings call transcript

Exact Sciences (EXAS)-1 Aug 23-2023 Q2 Earnings call transcript

Exact Sciences (EXAS)-9 May 23-2023 Q1 Earnings call transcript

Exact Sciences (EXAS)-21 Feb 23-2022 Q4 Earnings call transcript

Exact Sciences (EXAS)-4 Nov 22-2022 Q3 Earnings call transcript

Exact Sciences (EXAS)-2 Aug 22-2022 Q2 Earnings call transcript

Exact Sciences (EXAS)-27 Apr 22-2022 Q1 Earnings call transcript

Exact Sciences (EXAS)-23 Feb 22-2021 Q4 Earnings call transcript

Exact Sciences (EXAS)-3 Nov 21-2021 Q3 Earnings call transcript

Exact Sciences (EXAS)-29 Jul 21-2021 Q2 Earnings call transcript

Exact Sciences (EXAS)-5 May 21-2021 Q1 Earnings call transcript

Exact Sciences (EXAS)-17 Feb 21-2020 Q4 Earnings call transcript

Exact Sciences (EXAS)-30 Oct 20-2020 Q3 Earnings call transcript

Exact Sciences (EXAS)-30 Jul 20-2020 Q2 Earnings call transcript

Exact Sciences (EXAS)-6 May 20-2020 Q1 Earnings call transcript

Exact Sciences (EXAS)-12 Feb 20-2019 Q4 Earnings call transcript

Exact Sciences (EXAS)-29 Oct 19-2019 Q3 Earnings call transcript

Exact Sciences (EXAS)-29 Jul 19-2019 Q2 Earnings call transcript

Exact Sciences (EXAS)-30 Apr 19-2019 Q1 Earnings call transcript

Exact Sciences (EXAS)-21 Feb 19-2018 Q4 Earnings call transcript

Exact Sciences (EXAS)-31 Oct 18-2018 Q3 Earnings call transcript

Exact Sciences (EXAS)-1 Aug 18-2018 Q2 Earnings call transcript

Exact Sciences (EXAS)-26 Apr 18-2018 Q1 Earnings call transcript

Exact Sciences (EXAS)-22 Feb 18-2017 Q4 Earnings call transcript

Exact Sciences (EXAS)-30 Oct 17-2017 Q3 Earnings call transcript

Actual											-0.71	-0.58	-1.46	-2.79	-0.18	-1.03	-0.97	-1.28	-1.04	-0.94	-0.84	-0.72	-0.42	-0.45	0	-0.27	-0.6	-0.09	-0.21	-4.67	-0.54	-0.01	-0.1
Forecast											-0.5833	-0.6462	-0.5357	-0.1936	-0.9636	-0.7482	-0.8462	-0.84	-1.0964	-1.041	-1.0739	-0.7943	-0.7383	-0.4887	-0.4731	-0.4403	-0.481	-0.3397	-0.1987	-0.303	-0.3616	-0.1263	-0.0612
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-21.72%	+10.24%	-172.54%	-1341.12%	+81.32%	-37.66%	-14.63%	-52.38%	+5.14%	+9.70%	+21.78%	+9.35%	+43.11%	+7.92%	+100.00%	+38.68%	-24.74%	+73.51%	-5.69%	-1441.25%	-49.34%	+92.08%	-63.40%

EXAS(Delisted)

EXAS fundamentals

EXAS Q3 2025 Earnings

Earnings Call

You can ask Aime